Prostate cancer drug approved

The National Institute for Health and Clinical Excellence (Nice) has revised its recommendations on a drug to treat advanced prostate cancer.

The institute now says Abirateron, marketed as Zytiga, should be given to patients on the NHS.

Live updates

'Discounted price' led to cancer drug approval

During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.

This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.

These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.

– Sir Andrew Dillon, NICE chief executive


Cancer Research: 'Delighted by abiraterone decision'

We are delighted by today's decision to allow patients with advanced prostate cancer to receive abiraterone on the NHS.

This drug was discovered at the Institute of Cancer Research and is the result of more than two decades of dedicated work by our scientists and and collaborators.

In clinical trials of men with advanced prostate cancer who have already tried chemotherapy, it has been shown to extend life by an average of four months and improve quality of life.

– Professor Alan Ashworth, Institute of Cancer Research chief executive

Prostate cancer drug approved

Prostate cancer cells seen through a coloured scanning electron micrograph (SEM)

A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.

Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.

The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.

Back to top